FindTrial
Sign In

Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic

Childhood Asthma and Return to School: the September Epidemic Exacerbation in Israel.A Controlled Trial of the Effectiveness of Preventive Treatment With Symbicort or Budicort Turbuhaler

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01179152
Enrollment
225
Registered
2010-08-11
Start date
2010-09-30
Completion date
2012-10-31
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma Exacerbation

Keywords

asthma, september epidemic, children, preventive

Brief summary

During the second week of September( week 38 of the year)there are recorded data of exacerbation of asthma all over the world, including Israel. A short preventive treatment of 6 weeks may reduce asthma exacerbation in children,reduce primary care and ER visiting and hospitalization.

Detailed description

During the second week of September( week 38 of the year)there are recorded data of exacerbation of asthma all over the world, including Israel. A short preventive treatment of 6 weeks may reduce asthma exacerbation in children,reduce primary care and ER visiting and hospitalization. We will study the effectiveness of Budicort or Symbicort turbuhaler as a preventive treatment in children aged 6-18 years.

Interventions

DRUGBudesonide turbuhaler, Budesonide+Formoterol turbuhaler

Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler

Sponsors

Meir Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

age : 6-18 years suffering from asthma asthma exacerbation during 1/9/2009-15/10/2009 \-

Exclusion criteria

any chronic condition that can involve respiratory tract (other than asthma) treated as prevention with ICS or montelukast from July 2010 Treated with oral steroids during the August 2010 asthma exacerbation one week prior study inclusion

Design outcomes

Primary

MeasureTime frameDescription
reduction of asthma exacerbation during the study periodAn average time of 8 weeksless asthma exacerbation

Secondary

MeasureTime frameDescription
less primary care physician visitsAn average time of 8 weeksless primary care physician visits less ER visits less hospitalization due to asthma exacerbation

Countries

Israel

Contacts

Primary ContactAvner He Cohen, MD
hermanc@post.tau.ac.il972-3-9398200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026